Inovio Fundamentals

INO
 Stock
  

USD 2.01  0.04  1.95%   

Inovio Pharma fundamentals help investors to digest information that contributes to Inovio Pharma's financial success or failures. It also enables traders to predict the movement of Inovio Stock. The fundamental analysis module provides a way to measure Inovio Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inovio Pharma stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Inovio Pharma Weighted Average Shares is quite stable at the moment as compared to the past year. The company's current value of Weighted Average Shares is estimated at 225.32 Million. Weighted Average Shares Diluted is expected to rise to about 225.3 M this year, although the value of Consolidated Income will most likely fall to (311.6 M).

Inovio Z Score Analysis

Inovio Pharma's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 2019 2020 2021 2022 (projected)
Enterprise Value407.22 M1.4 B1.02 B827.4 M
Average Equity42.16 M288.91 M485.85 M524.21 M
Z Score 
 = 
Sum Of  
 
5 Factors 
More About Z Score | All Equity Analysis

Current Inovio Pharma Z Score

    
  0.3  
Most of Inovio Pharma's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inovio Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
First Factor
 = 
1.2 * (
Working Capital
/
Total Assets )
Second Factor
 = 
1.4 * (
Retained Earnings
/
Total Assets )
Thrid Factor
 = 
3.3 * (
EBITAD
/
Total Assets )
Fouth Factor
 = 
0.6 * (
Market Value of Equity
/
Total Liabilities )
Fifth Factor
 = 
0.99 * (
Revenue
/
Total Assets )
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition

According to the company's disclosures, Inovio Pharma has a Z Score of 0.3. This is 95.56% lower than that of the Healthcare sector and 91.02% lower than that of the Biotechnology industry. The z score for all United States stocks is 96.56% higher than that of the company.

Inovio Pharma Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Inovio Pharma's current stock value. Our valuation model uses many indicators to compare Inovio Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inovio Pharma competition to find correlations between indicators driving Inovio Pharma's intrinsic value. More Info.
Inovio Pharma is rated second overall in shares owned by insiders category among related companies. It is currently regarded as number one stock in beta category among related companies totaling about  0.61  of Beta per Shares Owned by Insiders. The ratio of Shares Owned by Insiders to Beta for Inovio Pharma is roughly  1.65 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Inovio Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Inovio Pharma's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inovio Pharma's earnings, one of the primary drivers of an investment's value.

Inovio Price to Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inovio Pharma's direct or indirect competition against its Price to Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inovio Pharma could also be used in its relative valuation, which is a method of valuing Inovio Pharma by comparing valuation metrics of similar companies.
Inovio Pharma is currently under evaluation in price to book category among related companies.

Inovio Pharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of Inovio Pharma from analyzing Inovio Pharma's financial statements. These drivers represent accounts that assess Inovio Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inovio Pharma's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(315.02 K)(336.69 K)(615.25 K)(633.42 K)(957.91 K)(1.03 M)
Revenue Per Employee150.79 K105.84 K21.2 K28.21 K5.6 K5.75 K
Average Assets175.77 M148.6 M162.93 M439.92 M569.6 M614.57 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(86.3 M)(90.77 M)(110.8 M)(153.95 M)(301.13 M)(309.06 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(84.71 M)(89.8 M)(106.15 M)(153.08 M)(296.99 M)(304.81 M)
Earnings before Tax(88.21 M)(94.8 M)(119.62 M)(166.41 M)(303.66 M)(311.65 M)
Average Equity133.42 M103.74 M42.16 M288.91 M485.85 M524.21 M
Enterprise Value349.64 M361.99 M407.22 M1.4 B1.02 B827.4 M
Free Cash Flow(73.5 M)(75.64 M)(98.84 M)(179.5 M)(216.94 M)(222.65 M)
Invested Capital111.52 M56.85 M175.07 M272.73 M378.94 M408.86 M
Invested Capital Average101.15 M73.22 M193.72 M265.22 M466.73 M503.57 M
Market Capitalization372.92 M381.39 M330.03 M1.5 B1.05 B863.97 M
Tangible Asset Value170.72 M115.84 M129.74 M526.11 M482.8 M520.92 M
Working Capital102.96 M52.52 M62.21 M429.46 M382.7 M412.92 M

Inovio Fundamentals

About Inovio Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Inovio Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inovio Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inovio Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Deferred Revenue86 K88.3 K
Revenues1.8 M1.8 M
Revenue to Assets 0.003579  0.003673 
Revenue Per Employee5.6 K5.7 K

Inovio Pharma Investors Sentiment

The influence of Inovio Pharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Inovio. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Inovio Pharma's public news can be used to forecast risks associated with investment in Inovio. The trend in average sentiment can be used to explain how an investor holding Inovio can time the market purely based on public headlines and social activities around Inovio Pharma. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Inovio Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Inovio Pharma's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Inovio Pharma's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Inovio Pharma.

Inovio Pharma Implied Volatility

    
  89.27  
Inovio Pharma's implied volatility exposes the market's sentiment of Inovio Pharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Inovio Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Inovio Pharma stock will not fluctuate a lot when Inovio Pharma's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Inovio Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Inovio Pharma's short interest history, or implied volatility extrapolated from Inovio Pharma options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inovio Pharma using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Inovio Pharma Piotroski F Score and Inovio Pharma Altman Z Score analysis. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for analysis

When running Inovio Pharma price analysis, check to measure Inovio Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inovio Pharma is operating at the current time. Most of Inovio Pharma's value examination focuses on studying past and present price action to predict the probability of Inovio Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inovio Pharma's price. Additionally, you may evaluate how the addition of Inovio Pharma to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Is Inovio Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharma. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
501.5 M
Quarterly Revenue Growth YOY
30.38
Return On Assets
(0.43) 
Return On Equity
(0.92) 
The market value of Inovio Pharma is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharma's value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharma's market value can be influenced by many factors that don't directly affect Inovio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Inovio Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.